HIV-fertőzés: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• CCR5 1
• CXCR4 0
• PD-1 2
• IL-15 1
• JAK 1
• STING 0
• GLP-1 2
• IL-17 0
• PD-L1 1
• TNF 0
• IL-6 0
• mTOR 1
• TP53 0
• NLRP3 0
• SGLT2 2
• STAT3 0
• AKT 0
• APOL1 0
• PCSK9 0
• PPAR 0
• CD40 1
• NRF2 0
• PI3K 0
• BCL-2 2
• CD19 1
• ERK 0
• HDAC 0
• HIF-1 0
• APOE 0
• BRD4 0
• FOXP3 0
• HSP90 0
• MAPK 0
• METTL3 0
• AMPK 0
• ATM 0
• BDNF 0
• CD20 0
• CD38 0
• CTNNB1 0
• FLT3 0
• HMGB1 0
• IL-1 0
• MET 0
• NMDA 0
• TIGIT 0
• VEGF 0
• ACE2 0
• ALK 0
• ANGPTL3 0
• AQP4 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CFTR 0
• COX-2 0
• CTLA-4 0
• DPP-4 0
• FTO 0
• G6PD 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Comparative and entangled histories of AIDS care in Austria and Slovenia, 1980s–2000s (AIDScare)

  Universitaet Graz· Graz, Ausztria· EU contribution 230 185 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Immunometabolic Reprogramming via a Gut-derived Organoid Platform (IRGOP)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2028. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  BRIDGING RESERVOIR SCIENCE, INTEGRATED DRUG DISCOVERY, BIG DATA ANALYTICS, ARTIFICIAL INTELLIGENCE AND EPIDEMIOLOGY (BRIDGE-HIV)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Hollandia· EU contribution 1 703 400 EUR· until 2030. szept.· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-CSA

  West African Network of Excellence for TB, AIDS and Malaria (WANETAM-4)

  European & Developing Countries Clinical Trials Partnership· Den Haag, Hollandia· EU contribution 12 751 885 EUR· until 2031. jún.· 14 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Defining the Landscape of Transcriptional Activity during HIV-1 Infection (DELTA-HIV)

  King's College London· London, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. máj.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Re-envisioning Vulnerability in HIV Care: Lived Experience, Emotional Meaning, and Service Innovation. (RE-HIV)

  Svenska Handelshogskolan· Helsinki, Finnország· EU contribution 226 277 EUR· until 2028. márc.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Pragmatic use of long-acting Oral Antiretrovirals in Africa (POA)

  The University Court of the University of St Andrews· St Andrews, Egyesült Királyság· EU contribution 5 499 083 EUR· until 2031. jan.· 6 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  EARLY NEUTRALIZING ANTIBODIES IN INFANTS LIVING WITH HIV TO ENHANCE THEIR LIFE (ENABLE)

  Servicio Madrileno de Salud· Madrid, Spanyolország· EU contribution 6 161 158 EUR· until 2029. dec.· 9 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  CHAPAS-5: An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in ART-naive and Treatment-experienced Viraemic Children and Adolescents Living with HIV in Africa

  University College London· London, Egyesült Királyság· EU contribution 6 587 149 EUR· until 2029. okt.· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  PrEP-ing at the end of HIV/AIDS: an anthropological study of Combination Prevention and PrEP in Argentina

  Freie Universitaet Berlin· Berlin, Németország· EU contribution 217 965 EUR· until 2027. szept.

10 of 25 running projects, newest first. Listed amounts together: 81,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 22
• Organoids 6
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 27
• Gene Expression Profiling 62
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 15
• Exome Sequencing 3
• Proteomics 37
• Metabolomics 33
• Mass Spectrometry 16
• Flow Cytometry 45
• Immunohistochemistry 15
• Xenograft Model Antitumor Assays 3
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 79
• Machine Learning 71
• Deep Learning 21
• Cohort Studies 426
• Genome-Wide Association Study 20

• Optimized Mass Spectrometry to Uncover M. tuberculosis Biomarkers in Extracellular Vesicles From Asymptomatic Tuberculosis Patients.

  J Infect Dis, 2026. aug.

• Altered bile acid metabolism in people with HIV correlates with systemic and intestinal inflammation.

  AIDS, 2026. júl.

• Portable mass spectrometry systems for point-of-care testing: technologies, applications, and clinical implementation.

  J Chromatogr B Analyt Technol Biomed Life Sci, 2026. jan.

• A novel model for predicting the risk of liver cirrhosis in people living with HIV/HBV coinfection: a study based on proteomic analysis.

  BMC Infect Dis, 2025. dec.

• Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study.

  AIDS Res Ther, 2017. márc.

• Ashwagandha (Withania somnifera) reverses β-amyloid1-42 induced toxicity in human neuronal cells: implications in HIV-associated neurocognitive disorders (HAND).

  PLoS One, 2013. okt.

• A cooperative and specific DNA-binding mode of HIV-1 integrase depends on the nature of the metallic cofactor and involves the zinc-containing N-terminal domain.

  Nucleic Acids Res, 2010. febr.

• Zinc finger proteins as templates for metal ion exchange: Substitution effects on the C-finger of HIV nucleocapsid NCp7 using M(chelate) species (M=Pt, Pd, Au).

  J Inorg Biochem, 2009. júl.

• Simultaneous determination of quercetin and its glycosides from the leaves of Nelumbo nucifera by reversed-phase high-performance liquid chromatography.

  Arch Pharm Res, 2009. márc.

• Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: a randomised, crossover, placebo-controlled study.

  Drugs R D, 2007. jan.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.